Alliance Early Phase (AEP) combines thought-leader expertise in conducting complex Phase 0-IIa trials across a range of patient and healthy populations.

We provide single- and two-site solutions for efficient study conduct, ensuring a synergistic approach to the clinical and scientific aspects of the trial.

Our two sites, CNS Network and Hassman Research Institute, exemplify operational excellence, providing clinical conduct of the highest quality, and pride themselves in moving at the ‘speed of business.’

Download the AEP fact sheet.

Download a presentation about AEP.

Leadership

Larry Ereshefsky, Pharm.D.
CSO, Early Phase Development
Hassman Research Institute and CNS Network

Dr. Ereshefsky is an internationally recognized thought leader in clinical translational central nervous system research with a proven track record in designing Phase I/IIA and clinical pharmacology studies. He is a leader in the application of translational drug development tools, and in the use of signal detection strategies to minimize placebo response. He is a retired Regents Professor of Pharmacy, Psychiatry, and Pharmacology from The University of Texas/UT Health Science Center. Subsequently, he was the VP, Principal Clinical Pharmacologist, and Global CNS Leader for Early Phase at PAREXEL.

David Walling, Ph.D.
CEO, Principal Investigator
CNS Network

Dr. Walling, a licensed clinical psychologist, has participated as a lead or co-investigator in hundreds of Phase I-IV clinical studies, with many focusing on schizophrenia, an indication for which he has KOL status. He has extensive experience advising leading pharmaceutical sponsors in many ways including the creation of drug development plans, design and analysis of clinical trials, and preparation for interactions with regulatory agencies. He has authored dozens of articles on psychiatric indications that have been published in leading scientific journals.

Howard Hassman, D.O.
CSO, Principal Investigator
Hassman Research Institute

Dr. Hassman, a Board-Certified Family Practitioner, has vast knowledge of clinical research with over 30 years of experience in the field. He has participated as a lead or co-investigator in hundreds of Phase I-IV clinical studies. He is considered an expert in the field of Psychopharmacology, and has an extensive background in psychodynamic psychotherapy, pain management, and addiction medicine. Dr. Hassman holds multiple advisory board memberships, and has authored numerous articles on psychiatric indications that have been published in leading psychiatric journals.

Research Sites

CNS Network
CNS Network is a clinical research group operating three outpatient clinics in the Los Angeles/Orange County area. The Long Beach facility offers a dedicated state-of-the-art Clinical Pharmacology Unit (CPU) with 60 beds, and a 30-bed Joint Commission-accredited inpatient Psychiatric Health Facility (PHF).

Hassman Research Institute
Hassman Research Institute is a clinical research site located on a large campus in Berlin, NJ. Its Early Phase Unit can house up to 40 subjects. Two separate wings provide the controlled environment needed to accommodate separate patient populations as well as translational studies.

Knowledge & Experience

Our KOLs have supported pharma with:

  • Clinical drug development planning
  • Clinical trials methodologies
  • PK/PD modeling
  • Experimental medicine strategies
  • Development, validation, and application of biomarkers
  • Vendor selection (Imaging, Electrophysiologic, cognitive sciences)

 

Specialized Studies

  • First-In-Man (FIM), Single ascending dose (SAD) and Multiple ascending dose (MAD)
  • Translational and experimental medicine studies
  • Adaptive and umbrella designs
  • Elderly and patient populations
  • Asian sensitivity and bridging in Japanese, Chinese, and Korean first-generation subjects
  • PK/PD
  • QTc, TQTc, cardiac monitoring
  • 505(b)(2) program strategies, biosimilars
  • Bioequivalence/Drug-Drug Interaction (DDI)/Food Effect
  • Devices

 

Technology/Capabilities

  • Imaging – PET, MRI, fMRI, MRS, MRE, FibroScan
  • Electrophysiology – EEG, PSG, and QEEG / ERP
  • Pain models in HNVs and patients
  • Digital Therapies – health devices, software, and applications
  • Safety – capnography, pulse ox, continuous safety EEGs, telemetry, biomarkers
  • Cognitive and behavioral assessments, including impairment of function
  • Driving Simulators
  • CSF collection

 

Therapeutic Areas

  • Healthy Volunteers: Including sub-populations of Asian, elderly, post-menopausal females, tobacco users
  • Psychiatry: ADHD, Anxiety, Bipolar, Depression, PTSD, Schizophrenia
  • Neurology: Alzheimer’s, Multiple Sclerosis, Parkinson’s, Post-Stroke, Sleep Disorders
  • Pain: Acute/Chronic, Fibromyalgia, Osteoarthritis, Migraine, Pain models such as UV and capsaicin
  • Human Abuse Liability: Addictions, Exploratory assessments, Definitive HAL testing
  • Asian Studies: Bridging to Japanese, Chinese, and other Asian populations
  • Impairment: Cognitive Dysfunction, Validated Driving Simulation studies
  • Internal Medicine: Endocrinology, Gastrointestinal, Immunology, Pulmonology, NASH/NAFLD, and more
  • Dermatology: Alopecia, Psoriasis, Acne, Atopic Dermatitis, Rosacea, Aesthetics

 

 

For more information or to further discuss your study needs please contact:
Bobbie Theodore, M.S.
Alliance Executive Director
(o) (916) 939-6696
(c) (916) 803-7149
bobbie@alliancesites.com